AGL 40.39 Increased By ▲ 0.38 (0.95%)
AIRLINK 127.00 Decreased By ▼ -0.99 (-0.77%)
BOP 6.62 Increased By ▲ 0.02 (0.3%)
CNERGY 4.52 Decreased By ▼ -0.08 (-1.74%)
DCL 8.61 Increased By ▲ 0.13 (1.53%)
DFML 41.72 Increased By ▲ 0.24 (0.58%)
DGKC 86.90 Increased By ▲ 0.32 (0.37%)
FCCL 32.35 Increased By ▲ 0.21 (0.65%)
FFBL 65.25 Decreased By ▼ -0.17 (-0.26%)
FFL 10.19 Decreased By ▼ -0.06 (-0.59%)
HUBC 110.00 Decreased By ▼ -0.49 (-0.44%)
HUMNL 14.65 Decreased By ▼ -0.10 (-0.68%)
KEL 5.13 No Change ▼ 0.00 (0%)
KOSM 7.51 Increased By ▲ 0.39 (5.48%)
MLCF 41.52 Decreased By ▼ -0.13 (-0.31%)
NBP 59.60 Decreased By ▼ -0.49 (-0.82%)
OGDC 194.70 Increased By ▲ 0.01 (0.01%)
PAEL 28.20 Increased By ▲ 0.25 (0.89%)
PIBTL 7.82 Decreased By ▼ -0.18 (-2.25%)
PPL 152.42 Increased By ▲ 1.25 (0.83%)
PRL 26.53 Decreased By ▼ -0.35 (-1.3%)
PTC 16.10 Increased By ▲ 0.10 (0.63%)
SEARL 79.50 Increased By ▲ 1.30 (1.66%)
TELE 7.47 Increased By ▲ 0.08 (1.08%)
TOMCL 35.42 Decreased By ▼ -0.25 (-0.7%)
TPLP 8.25 Increased By ▲ 0.34 (4.3%)
TREET 16.08 Increased By ▲ 0.19 (1.2%)
TRG 52.75 Decreased By ▼ -0.01 (-0.02%)
UNITY 26.79 Increased By ▲ 0.24 (0.9%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 9,892 Decreased By -28 (-0.28%)
BR30 30,712 Decreased By -39.5 (-0.13%)
KSE100 93,338 Increased By 113 (0.12%)
KSE30 28,932 Increased By 46.8 (0.16%)
World

Pfizer says third COVID-19 shot warranted in FDA document

  • Pfizer says data from its own clinical trials shows that the vaccine efficacy had waned by around 6 percent every two months after the second dose
Published September 15, 2021

Pfizer Inc said that US regulators should approve a third booster dose of the COVID-19 vaccine it developed with Germany's BioNTech SA six months after the second dose due to waning effectiveness of the shot over time, according to documents the drugmaker submitted to the US Food and Drug Administration.

The FDA released the documents on Wednesday ahead of a meeting by an outside panel of experts on Friday to vote on whether or not to recommend U.S regulators approve the extra shots.

EU says COVID boosters may have higher legal risks without EMA approval

Pfizer said data from its own clinical trials showed that the vaccine efficacy had waned by around 6 percent every two months after the second dose. It also said the incidence of breakthrough cases in that trial was higher among people who received their shots earlier.

The drugmaker also pointed to real world data from Israel and the United States showing declining effectiveness of the vaccine.

Moderna developing single-dose booster shot for COVID-19 and flu

It said that a roughly 300-participant clinical trial showed that the third dose generated a better immune response than the second dose. It also pointed to data from the booster program recently started in Israel to show that a third dose restores high levels of protection from the virus.

The FDA has not yet published the briefing with its view on the issue.

Comments

Comments are closed.